CNBC Daily Open: Oil deals and awaiting tech earnings

Markets start the week with optimism ahead of earnings reports from large tech companies and as Chevron bets big with Hess.

CNBC Daily Open: Oil deals and awaiting tech earnings

On April 26, 2023, traders work at the New York Stock Exchange in New York City.

This report comes from CNBC Daily Open today, our new international markets newsletter. CNBC Daily Open keeps investors informed about everything they need to be aware of, wherever they may be. You like what you see? Subscribe to our newsletter

Here is a link to the article


Markets try to comeback

The Nasdaq composite snapped at a

four-day losing streak

Treasury yields fell from their highest levels on Monday. Investors were waiting for the announcement of corporate earnings by tech giants such as


You can also find out more about the following:


Europe's Stoxx 600 Index ended

The price is slightly lower

The European Central Bank will announce its monetary policy decisions later this week, amid the geopolitical uncertainties and in advance of that decision.

Another mega-merger in the oil industry


On Monday, it was announced that the company had agreed to purchase


53% of the world's population is estimated to be worth $53 billion

Stock. The proposed mega merger is the second among the largest U.S. oil companies after

Exxon Mobil

Bid $60 billion for

Pioneer Natural Resources

Earlier this month. The proposed deal will also increase competition between Chevron & Exxon for drilling in Guyana, a new producer.

Nvidia's latest blow against Intel


The company is developing personal computer chips that would incorporate technology from

Arm Holdings


Reuters reported

The plans were announced on Monday. The chipmaker will challenge



Longtime stronghold

Personal computers are a growing market.

Advanced Micro Devices

Also, according to reports, plans are in place to produce chips for PCs using Arm technology.

Tesla discloses DOJ probes


The U.S. Department of Justice is investigating certain cases,

issued subpoenas

Elon Musk's carmaker. In a third quarter

financial filing

Tesla announced on Monday that the department will be looking at its driver assistance system, marketed as Autopilot, and Full Self-Driving (or FSD) options, the range of electric vehicles offered by the company, as well as the "personal benefits" and "related parties" and "personnel decision-making".

Goldman's Guide to 5% 10 Year Yield

The Federal Reserve has been signaling higher rates longer to fight inflation. The benchmark 10-year interest rate briefly

The key 5% threshold was surpassed

According to, investors should look for stocks with strong balance sheet as they tend to be more resistant to high interest rates.

Goldman Sachs


The Nasdaq closed higher for the first session in five after a week of market activity. Chevron made a big bet on Monday to buy Hess in order to compete with Exxon Mobil, a larger competitor.

Stocks are under pressure.


Concerns about the impact of rising Treasury yields on the American economy. Some analysts believe the benchmark 10-year rate could have more room to rise.

Tony Dwyer, Canaccord Genuity's chief market strategist, said that the rapid rise in yields would "accelerate an already weakening economy that was masked by increased rates."

UBS sees Microsoft as a possible hedge. Microsoft is scheduled to release its earnings Tuesday after the close.

Recession is not the only thing to worry about

Next year, we'll be able to see a significant increase in the number of people who are employed. Microsoft, unlike more focused software firms, "has full geographical coverage across all industry sectors," UBS analyst Karl Keirstead stated, making Microsoft less vulnerable to downturns within any particular sector or region. Alphabet will also report its quarterly results on Tuesday afternoon.

Wall Street analysts have also made new predictions on what has become one of the hottest segments this year in pharmaceuticals.

weight loss drugs


Analysts predict that sales of weight-loss drugs like Wegovy and Mounjaro will easily surpass $100 billion. Citi has recently increased its estimates of sales for these drugs from $55 billion to $71 billion in 2035. This is still a conservative estimate compared to Guggenheim’s sales expectations of $150 to $200 billion.

The most valuable company in Europe listed on the stock exchange.

Novo Nordisk

Wegovy is sold under the name Ozempic. U.S. drugmaker

Eli Lilly

makes Mounjaro.